Aligos Therapeutics has been granted a patent for compounds of Formula I, pharmaceutical compositions containing these compounds, and methods for treating diseases by administering them. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11858913B2) discloses a compound of Formula I, along with various stereoisomers, tautomers, and pharmaceutically acceptable salts thereof. The compound is characterized by the formation of non-aromatic monocyclic or polycyclic rings, optionally substituted with halogen, alkyl, or cycloalkyl groups. Additionally, the patent claims a pharmaceutical composition containing the compound along with suitable excipients for potential therapeutic applications.
Furthermore, the patent encompasses specific variations of the compound, including different substituents on the monocyclic rings formed by R1 and R2, as well as variations in R3, R4, R5, R7, and R8 groups. The disclosed compounds exhibit diverse structural features, such as partially unsaturated carbocyclic or heterocyclic rings, aryl rings, or heteroaryl rings. The patent also includes specific examples of compounds within the scope of the claims, highlighting their potential utility in pharmaceutical formulations.
To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
